To prospectively evaluate the clinical impact and the diagnostic performance of FCH-PET/CT in patients with occult biochemical recurrence of prostate cancer (PCa).
Results of 179 patients (mean PSA = 7. 5ng/mL) with negative/inconclusive results of pelvic-MRI and of bone-scintigraphy were analysed. To determine the impact of FCH-PET/CT on diagnostic thinking and on patient management, the referring physicians prospectively filled-in a 1st and 2nd questionnaire related to patient's planned management before and after FCH-PET/CT. Based on data from a 6-month follow-up after FCH-PET/CT, an independent assessor blinded to results of FCH-PET/CT determined the adequacy of management changes motivated by FCH-PET/CT.
FCH-PET/CT localised foci evocative of recurrent PCa in 59% (105/179) of patients. Results of FCH-PET/CT motivated a change in scheduled patient management in 56% (100/179) of patients; which was considered as adequate in 89% (89/100) of patients. FCH-PET/CT also led to the detection of lung cancer in two patients.
FCH PET/CT is a powerful tool to localise the sites of occult biochemical recurrence of PCa, leading to an adequate management change in half of patients.
PloS one. 2018 Feb 09*** epublish ***
Quentin Gillebert, Virginie Huchet, Caroline Rousseau, Alexandre Cochet, Pierre Olivier, Frédéric Courbon, Eric Gontier, Valérie Nataf, Sona Balogova, Jean-Noël Talbot, other ICHOROPRO investigators
Department of Nuclear Medicine, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris & Université Pierre et Marie Curie, Paris, France., Nuclear Medicine Unit, ICO Cancer Center, Saint Herblain, France., Department of Nuclear Medicine, Centre GF Leclerc, Dijon, France., Department of Nuclear Medicine, CHU Brabois, Vandoeuvre-lès-Nancy, France., Department of Nuclear Medicine, Institut Claudius Regaud, Toulouse, France., Department of Nuclear Medicine, HIA Val-de-Grâce, Paris, France.